1 / 22

The Impact of the VGDS voluntary genomic data submission process at the FDA. A tool for enabling change in non-clinical

gazit
Download Presentation

The Impact of the VGDS voluntary genomic data submission process at the FDA. A tool for enabling change in non-clinical

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    1. The Impact of the VGDS (voluntary genomic data submission) process at the FDA. A tool for enabling change in non-clinical and clinical drug development processes. Panel A- The Promise of the Post-Genomic Era: The Development of Personalized Medicine May 4, 2006 Michael Orr, Ph.D., DABT Office of Clinical Pharmacology, Genomics Center for Drug Evaluation and Research U.S. Food and Drug Administration

    2. 2 Disclaimer The views expressed in this presentation are the ones of the author and may not necessarily reflect the position of the U.S. Food and Drug Administration.

More Related